Diagnostics

Beacon Biosignals Acquires Snap Diagnostics, Paving the Way for EEG-Enabled Home Sleep Testing in Every Care Setting

Acquisition more than doubles Beacon’s patient reach, creating a national channel to bring EEG-enabled home sleep testing to primary care,...

DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies

Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion...

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Custom Health to Close the Market at the TSX on October 22, 2026, and Announces Appointments of Chief Commercial and Strategy Officer and Chief Compliance and Regulatory Officer

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpretation to generate clearer mechanistic...

EY Pulse of the MedTech Industry Report 2026: Blockbuster performers and innovation drive record MedTech industry growth

Broader MedTech industry at turning point, seeking positioning to optimize portfolios, differentiate technology and improve R&DInnovation drives increased dealmaking and...

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis)...

error: Content is protected !!